Table 2.
Definition and data range of variables in the model.
| Field | Definition of field | Data range/class | Total N = 561 Mean ± SD/N (%) | Live birth N = 237 Mean ± SD/N (%) | No live birth N = 324 Mean ± SD/N (%) | P-value |
|---|---|---|---|---|---|---|
| Basic characteristics panel | ||||||
| Female age (years) | Female age at time of conception | 19–47 | 34.67 ± 4.39 | 33.73 ± 4.08 | 35.35 ± 4.48 | <0.001 |
| Female BMI (kg/m2) | Female body mass index | 15.2–48.68 | 21.69 ± 3.01 | 21.55 ± 3.27 | 21.79 ± 2.80 | 0.166 |
| Kayrotype of couple | Kayrotype analysis of couple | {Normal, abnormal} | Abnormal: 48 (8.60%) Normal: 510 (91.40%) |
Abnormal: 22 (9.36%) Normal: 213 (90.64%) |
Abnormal: 26 (8.05%) Normal: 297 (91.95%) |
0.585 |
| Autoantibodies panel | ||||||
| aβ 2 GPI-IgM (U/ml) | Concentration of aβ 2 GPI-IgM | 0.27–287 | 10.53 ± 19 | 12.9 ± 20.48 | 8.79 ± 17.68 | 0.418 |
| aβ 2 GPI-IgG (U/ml) | Concentration of aβ 2 GPI-IgG | 0.1–133.87 | 1.25 ± 5.86 | 1.3 ± 8.36 | 1.21 ± 2.92 | <0.001 |
| aCL-IgM (MPL) | Concentration of anti-cardiolipin antibody -IgM | 0.13–104.75 | 4.69 ± 4.46 | 4.68 ± 4.62 | 4.7 ± 4.35 | 0.690 |
| aCL-IgG (GPL) | Concentration of anti-cardiolipin antibody -IgG | 0.23–102 | 5.16 ± 5.21 | 6.15 ± 3.84 | 4.43 ± 5.91 | <0.001 |
| aTG (IU/ml) | Concentration of anti-thymocyte globulin | 0–1,801 | 87.25 ± 191.56 | 96.37 ± 204.4 | 80.57 ± 181.63 | 0.246 |
| aTPO (IU/ml) | Concentration of anti-thyroidperoxidase antibodies | 0–1,300 | 34.3 ± 75.4 | 35.44 ± 63.79 | 33.46 ± 82.95 | 0.393 |
| SSA (U/ml) | Concentration of SSA | 0–251 | 12.2 ± 18.66 | 13.36 ± 23.15 | 11.36 ± 14.50 | 0.471 |
| SSB (U/ml) | Concentration of SSB | 1–430 | 8.26 ± 8.53 | 8.45 ± 11.17 | 8.11 ± 5.9 | 0.060 |
| Sm (U/ml) | Concentration of Sm | 1–207 | 6.5 ± 4.8 | 6.99 ± 5.39 | 6.14 ± 4.3 | 0.169 |
| RNP (U/ml) | Concentration of ribonucleoprotein | 1–754 | 23.36 ± 27.12 | 25.23 ± 23.63 | 21.98 ± 29.37 | 0.008 |
| Scl-70 (U/ml) | Concentration of Scl-70 | 1–212 | 15.2 ± 15.98 | 14.97 ± 13.06 | 15.37 ± 17.84 | 0.596 |
| Jo1 (U/ml) | Concentration of Jo1 | 2–384 | 19.73 ± 28.13 | 19.96 ± 25.72 | 19.55 ± 29.81 | 0.862 |
| dsDNA (U/ml) | Concentration of double-stranded DNA | 0–112 | 16.09 ± 14.45 | 15.76 ± 15.61 | 16.33 ± 13.56 | 0.097 |
| Centromeric B (U/ml) | Concentration of centromeric B | 0–232 | 13.32 ± 14.7 | 14.03 ± 18.42 | 12.81 ± 11.24 | 0.940 |
| histones (U/ml) | Concentration of histones | 1–78 | 8.24 ± 5.8 | 8.07 ± 5.27 | 8.37 ± 6.16 | 0.774 |
| Peripheral immunology panel | ||||||
| D2 (ng/ml) | Concentration of D-dimer | 45.36–30161.82 | 224.73 ± 188.95 | 228.1 ± 215.39 | 222.26 ± 167.29 | 0.809 |
| ADP (%) | Platelet aggregation rate when ADP is used as an aggregator | 5.7–98.9 | 75.82 ± 13.31 | 76.17 ± 12.81 | 75.56 ± 13.67 | 0.860 |
| Col (%) | Platelet aggregation rate when Col is used as an aggregator | 0.1–100 | 75.44 ± 20.15 | 75.46 ± 20.28 | 75.42 ± 20.08 | 0.406 |
| ARA (%) | Platelet aggregation rate when ARA is used as an aggregator | 0–100 | 59.05 ± 36.07 | 59.04 ± 34.19 | 59.06 ± 37.43 | 0.234 |
| IgG T (%) | The percentage of IgG+ T cells in T cells | 0.1–100 | 41.98 ± 35.35 | 47.13 ± 34.53 | 38.22 ± 35.52 | 0.001 |
| IgG B (%) | The percentage of IgG+ B cells in B cells | 0.8–100 | 62.16 ± 29.66 | 66.46 ± 27.24 | 59.01 ± 30.98 | 0.006 |
| IFN-r (%) | The percentage of IFN-r+ Th cells in Th cells | 3.6–67.8 | 22.53 ± 7.6 | 22.19 ± 6.82 | 22.78 ± 8.12 | 0.824 |
| TNF-a (%) | The percentage of TNF-a+ Th cells in Th cells | 5.1–84.4 | 38.88 ± 9.74 | 37.4 ± 8.88 | 39.97 ± 10.19 | 0.003 |
| NK cytotoxicity 50:1 | NK cytotoxicity to K562 at E: T ratio of 50:1 | 3.1–79.7 | 34.57 ± 12.5 | 36.39 ± 11.32 | 33.24 ± 13.15 | 0.005 |
| NK cytotoxicity 25:1 | NK cytotoxicity to K562 at E: T ratio of 25:1 | 1.4–76.2 | 23.42 ± 10.39 | 24.95 ± 9.98 | 22.3 ± 10.56 | 0.005 |
| T (%) | The percentage of T cells in CD45+ lymphocytes | 35.81–999.62 | 126.23 ± 194.65 | 138.04 ± 204.95 | 117.59 ± 186.61 | <0.001 |
| Tc (%) | The percentage of Tc cells in CD45+ lymphocytes | 11.37–59.34 | 27.18 ± 6.1 | 27.08 ± 5.84 | 27.26 ± 6.3 | 0.908 |
| Th (%) | The percentage of Th cells in CD45+ lymphocytes | 16.77–62.96 | 37.04 ± 5.79 | 37.13 ± 5.88 | 36.98 ± 5.74 | 0.765 |
| NK (%) | The percentage of NK cells in CD45+ lymphocytes | 1.32–54.99 | 15.18 ± 5.07 | 15.02 ± 4.98 | 15.29 ± 5.14 | 0.674 |
| B (%) | The percentage of B cells in CD45+ lymphocytes | 3.68–33.49 | 13.72 ± 3.77 | 13.76 ± 3.7 | 13.68 ± 3.83 | 0.868 |
| CD4/CD8 | The ratio of Th cells and Tc cells | 0.34–3.62 | 1.47 ± 0.49 | 1.48 ± 0.48 | 1.46 ± 0.5 | 0.346 |
| T (No.) | The absolute number of T cells per 100 μl blood | 362.78–5999.08 | 1582.8 ± 487.26 | 1557.77 ± 475.69 | 1601.1 ± 495.48 | 0.213 |
| Tc (No.) | The absolute number of Tc cells per 100 μl blood | 104.86–3142.96 | 614.74 ± 231.03 | 600.82 ± 199.57 | 624.92 ± 251.38 | 0.872 |
| Th (No.) | The absolute number of Th cells per 100 μl blood | 241.58–3175.38 | 844.39 ± 302.62 | 836.67 ± 327.13 | 850.03 ± 283.73 | 0.277 |
| NK (No.) | The absolute number of NK cells per 100 μl blood | 33.95–1907.72 | 344.6 ± 160.4 | 335.25 ± 155.15 | 351.45 ± 164.04 | 0.133 |
| B (No.) | The absolute number of B cells per 100 μl blood | 61.78–1731.29 | 320.43 ± 167.27 | 318.54 ± 180.53 | 321.82 ± 157.14 | 0.639 |
| Endometrial immunology panel | ||||||
| HE | Histological dating | {Inconformity, early, mid, late} | Inconformity: 27 (20.00%) Early: 1 (0.74%) Mid: 106 (78.52%) Late: 1 (0.74%) |
Inconformity: 2 (25.00%) Early: 0 (0%) Mid: 6 (75.00%) Late: 0 (0%) |
Inconformity: 25 (19.69%) Early: 1 (0.79%) Mid: 100 (78.74%) Late: 1 (0.79%) |
0.949 |
| CD56 (%) | The percentage of CD56+ cells in total endometrial cells | 0.5–58.77 | 13.13 ± 6.94 | 13.8 ± 7.35 | 12.64 ± 6.6 | 0.051 |
| Foxp3 (%) | The percentage of Foxp3+ cells in total endometrial cells | 0.01–1.11 | 0.1 ± 0.06 | 0.1 ± 0.06 | 0.1 ± 0.06 | 0.891 |
| CD68 (%) | The percentage of CD68+ cells in total endometrial cells | 0.15–12.32 | 2.22 ± 0.95 | 1.95 ± 0.94 | 2.41 ± 0.92 | <0.001 |
| CD163 (%) | The percentage of CD163+ cells in total endometrial cells | 0.5–10 | 2.64 ± 1.2 | 2.81 ± 1.34 | 2.53 ± 1.08 | 0.015 |
| CD1a (%) | The percentage of CD1a+ cells in total endometrial cells | 0–0.612 | 0.07 ± 0.06 | 0.07 ± 0.05 | 0.08 ± 0.06 | 0.030 |
| CD83 (%) | The percentage of CD83+ cells in total endometrial cells | 0.09–11.37 | 2 ± 1.01 | 1.88 ± 1.1 | 2.08 ± 0.93 | <0.001 |
| CD57 (%) | The percentage of CD57+ cells in total endometrial cells | 0.02–2.66 | 0.39 ± 0.24 | 0.35 ± 0.22 | 0.41 ± 0.25 | 0.002 |
| CD8 (%) | The percentage of CD8+ cells in total endometrial cells | 0.53–18.27 | 3.14 ± 1.65 | 2.8 ± 1.6 | 3.38 ± 1.65 | <0.001 |
| CD138 | The intensity of CD138+ cells in endometrial tissue | {–, ±, +} | –: 496 (96.88%) ±: 2 (0.39%) +: 14 (2.73%) |
–: 190 (98.45%) ±: 2 (1.04%) +: 1 (0.52%) |
–: 306 (95.92%) ±: 0 (0%) +: 13 (4.08%) |
0.004 |
| Hormone panel | ||||||
| FSH (mIU/ml) | Concentrationn of follicle-stimulating hormone | 0.97–59.62 | 7.31 ± 3.49 | 7.3 ± 4.24 | 7.31 ± 2.82 | 0.593 |
| LH (mIU/ml) | Concentrationn of luteal hormone | 0.35–48.96 | 5.14 ± 3.34 | 5.51 ± 4.26 | 4.87 ± 2.42 | 0.069 |
| E2 (pg/ml) | Concentration of estrogen | 0.29–1,778 | 52.12 ± 69.45 | 46.02 ± 36.55 | 56.57 ± 85.67 | 0.773 |
| P (ng/ml) | Concentration of progesterone | 0.03–59.02 | 0.83 ± 2.59 | 0.81 ± 2.49 | 0.84 ± 2.66 | 0.004 |
| PRL (ng/ml) | Concentration of prolactin | 0.3–1,249 | 37.69 ± 90.22 | 36.14 ± 68.48 | 38.83 ± 103.35 | 0.023 |
| T (ng/ml) | Concentration of testerone | 0–71.42 | 1.63 ± 6.07 | 1.47 ± 5.59 | 1.75 ± 6.4 | 0.083 |
| TSH (μIU/ml) | Concentration of thyroid stimulating hormone | 0.01–25.33 | 2.32 ± 1.01 | 2.29 ± 1.04 | 2.35 ± 1 | 0.138 |
| FT3 (pg/ml) | Concentration of free triiodothyronine | 1.01–301.2 | 3.11 ± 0.5 | 3.08 ± 0.46 | 3.14 ± 0.52 | 0.370 |
| FT4 (ng/dl) | Concentration of free thyroxine | 0.71–84.88 | 2.01 ± 2.42 | 1.88 ± 2.37 | 2.1 ± 2.45 | 0.002 |
| Embryo panel | ||||||
| ways to conceive | IVF-ET or natural conception | {IVF-ET, natural conception} | IVF-ET: 517 (92.16%) Natural conception: 44 (7.84%) |
IVF-ET: 215 (90.72%) Natural conception: 22 (9.28%) |
IVF-ET: 302 (93.21%) Natural conception: 22 (6.79%) |
0.278 |
| Endometrial preparation programs | Endometrial preparation programs during IVF-ET cycle | {Hormone-replacement cycle, natural cycle, others} | Hormone-replacement cycle: 200 (43.67%) Natural cycle: 113 (24.67%) Others: 145 (31.66%) |
Hormone-replacement cycle: 79 (47.59%) Natural cycle: 46 (27.71%) Others: 41 (24.70%) |
Hormone-replacement cycle: 121 (41.44%) Natural cycle: 67 (22.95%) Others: 104 (35.62%) |
0.050 |
| Fertilization way | Fertilization method to get embryo | {ICSI, IVF} | ICSI: 154 (32.56%) IVF: 319 (67.44%) |
ICSI: 54 (27.69%) IVF: 141 (72.31%) |
ICSI: 100 (35.97%) IVF: 178 (64.03%) |
0.059 |
| Type of embryo | Type of embryo | {Blastosphere, cleavage stage embryo} | Blastosphere: 324 (62.43%) Cleavage stage embryo: 195 (37.57%) |
Blastosphere: 148 (69.48%) Cleavage stage embryo: 65 (30.52%) |
Blastosphere: 176 (57.52%) Cleavage stage embryo: 130 (42.48%) |
0.006 |
| Type of transfer | Embryo transfer or frozen embryo transfer | {ET, FET} | ET: 53 (10.27%) FET: 463 (89.73%) |
ET: 40 (18.96%) FET: 171 (81.04%) |
ET: 13 (4.26%) FET: 292 (95.74%) |
<0.001 |
| No. of transferred embryo | The number of transferred embryos in one transfer cycle | 1–3 | 1.8 ± 0.55 | 1.88 ± 0.57 | 1.73 ± 0.53 | 0.012 |
| Quality of embryo | Quality of transferred embryo | {Sequence 1,2,3,4,5}a | 1: 624 (68.95%) 2: 244 (26.96%) 3: 32 (3.54%) 4: 4 (0.44%) 5: 1 (0.11%) |
1: 296 (75.32%) 2: 84 (21.37%) 3: 12 (3.05%) 4: 1 (0.25%) 5: 0 (0%) |
1: 328 (64.06%) 2: 160 (31.25%) 3: 20 (3.91%) 4: 3 (0.59%) 5: 1 (0.2%) |
0.006 |